Evidence map›Paper›PMID 35971109›Full record

ArticleBMC infectious diseases2022

Patient experiences of sexual dysfunction after transition to dolutegravir-based HIV treatment in mid-Western Uganda: a qualitative study.

Henry Zakumumpa, Ronald Kiguba, Helen Byomire Ndagije, Gilbert Ategeka, Jacquellyn Nambi Ssanyu, Freddy Eric Kitutu

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Henry ZakumumpaSchool of Public Health, Makerere University College of Health Sciences, Kampala, Uganda. zakumumpa.henry09@gmail.com.
Ronald KigubaDepartment of Pharmacology and Therapeutics, Makerere University College of Health Sciences, Kampala, Uganda.
Helen Byomire NdagijeNational Drug Authority, Directorate of Product Safety, Kampala, Uganda.
Gilbert AtegekaART Clinic, Fort Portal Regional Referral Hospital, Fort Portal, Uganda.
Jacquellyn Nambi SsanyuSustainable Pharmaceutical Systems Unit, Makerere University College of Health Sciences, Kampala, Uganda.
Freddy Eric KitutuSustainable Pharmaceutical Systems Unit, Makerere University College of Health Sciences, Kampala, Uganda.
Makerere University · UGFort Portal Hospital · UG

Funding

Uppsala Monitoring Centre CARTA/2020/354.707A
6 · The paper itself

Abstract

backgroundThe literature on dolutegravir (DTG)-based HIV treatment has focused on assessing therapeutic efficacy particularly with regard to viral load suppression. However, little empirical attention has been devoted to understanding the effects of DTG on quality of life, in particular sexual health and functioning in PLHIV. This study focused on understanding patient experiences of sexual dysfunction, after transition to DTG-based regimens in Rwenzori region in Mid-Western Uganda.

methodsWe adopted a qualitative exploratory research design. Between August and September 2021, we conducted sixteen in-depth interviews and six focus group discussions (48 participants) with patients reporting 'new' sexual dysfunction after transition to DTG-based regimens at seven health facilities in mid-Western Uganda. Data were analyzed by thematic approach.

resultsDecreased libido was reported in both sexes of patients within weeks of transition to DTG-based regimens. Diminished interest in sex was more frequently reported among women while men complained of a marked reduction in the frequency of sex. Women reported loss of psycho-social attraction to their long-term male partners. Erectile dysfunction was common among men in this sample of patients. Patients described their experiences of sexual dysfunction as an affront to their socially-constructed gender identities. Patients described tolerating sexual adverse drug reactions (ADRs) as a necessary tradeoff for the extension in life granted through antiretroviral therapy. A number of women reported that they had separated from their spouses as a result of perceived drug-induced sexual dysfunction. Marital strife and conflict arising from frustration with sexual-partner dysfunction was frequently reported by participants in both sexes. Several participants indicated experiencing insecurity in their heterosexual relationships due to difficulties in sexual functioning.

conclusionSexual dysfunction following transition to DTG-based regimens is common in both sexes of PLHIV, who indicated that they had no prior experience of difficulties in sexual health. Our findings demonstrate that sexual ADRs negatively impact self-esteem, overall quality of life and impair gender relations. DTG-related sexual health problems merit increased attention from HIV clinicians. Further research is warranted to assess the prevalence of DTG-associated sexual dysfunction in patients in Uganda.

Indexed as

HIV InfectionsQuality of LifeDolutegravirFemaleHeterocyclic Compounds, 3-RingHumansMaleOxazinesPatient Outcome AssessmentPiperazinesPyridonesUgandaDolutegravirHeterocyclic Compounds, 3-RingOxazinesPiperazinesPyridonesAntiretroviral therapyDolutegravirHIVPatient safetyPharmacovigilance

Identifiers

PMID35971109
PMCPMC9377131
OpenAlexW4291890762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.